Thompson Investment Management Inc. lifted its stake in shares of CVS Health (NYSE:CVS) by 2.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 93,191 shares of the pharmacy operator’s stock after purchasing an additional 1,910 shares during the period. CVS Health accounts for 1.1% of Thompson Investment Management Inc.’s investment portfolio, making the stock its 29th biggest holding. Thompson Investment Management Inc.’s holdings in CVS Health were worth $5,797,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently modified their holdings of the company. Thompson Siegel & Walmsley LLC boosted its holdings in CVS Health by 16.7% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 122,422 shares of the pharmacy operator’s stock worth $9,955,000 after buying an additional 17,475 shares during the period. Girard Partners LTD. boosted its holdings in CVS Health by 2.7% in the 3rd quarter. Girard Partners LTD. now owns 66,690 shares of the pharmacy operator’s stock worth $5,423,000 after buying an additional 1,775 shares during the period. Exencial Wealth Advisors LLC boosted its holdings in CVS Health by 36.1% in the 3rd quarter. Exencial Wealth Advisors LLC now owns 43,147 shares of the pharmacy operator’s stock worth $3,509,000 after buying an additional 11,436 shares during the period. Pacer Advisors Inc. boosted its holdings in CVS Health by 7.8% in the 3rd quarter. Pacer Advisors Inc. now owns 35,097 shares of the pharmacy operator’s stock worth $2,854,000 after buying an additional 2,543 shares during the period. Finally, Walter & Keenan Financial Consulting Co. MI ADV boosted its holdings in CVS Health by 7.1% in the 3rd quarter. Walter & Keenan Financial Consulting Co. MI ADV now owns 13,600 shares of the pharmacy operator’s stock worth $1,106,000 after buying an additional 900 shares during the period. Institutional investors own 83.34% of the company’s stock.
In other news, Director C David Brown II purchased 10,000 shares of the business’s stock in a transaction on Friday, May 4th. The stock was purchased at an average cost of $61.99 per share, with a total value of $619,900.00. Following the acquisition, the director now directly owns 101,252 shares in the company, valued at $6,276,611.48. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 0.53% of the stock is owned by company insiders.
Shares of CVS Health opened at $65.62 on Wednesday, Marketbeat reports. The company has a quick ratio of 1.88, a current ratio of 2.37 and a debt-to-equity ratio of 1.59. CVS Health has a one year low of $60.14 and a one year high of $84.00. The firm has a market capitalization of $66.59 billion, a price-to-earnings ratio of 11.12, a PEG ratio of 0.98 and a beta of 1.02.
CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 2nd. The pharmacy operator reported $1.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.09. CVS Health had a net margin of 3.59% and a return on equity of 17.45%. The firm had revenue of $45.69 billion during the quarter, compared to the consensus estimate of $45.77 billion. During the same period last year, the firm earned $1.17 EPS. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. equities analysts expect that CVS Health will post 6.99 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, May 3rd. Shareholders of record on Monday, April 23rd were issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 3.05%. The ex-dividend date of this dividend was Friday, April 20th. CVS Health’s payout ratio is 33.90%.
Several research analysts recently commented on CVS shares. Mizuho set a $95.00 price objective on shares of CVS Health and gave the stock a “buy” rating in a report on Wednesday, January 24th. Needham & Company LLC raised shares of CVS Health from a “buy” rating to a “strong-buy” rating and raised their price objective for the stock from $88.00 to $100.00 in a report on Tuesday, January 30th. ValuEngine downgraded shares of CVS Health from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Royal Bank of Canada set a $89.00 price objective on shares of CVS Health and gave the stock a “buy” rating in a report on Thursday, February 8th. Finally, Robert W. Baird cut their price objective on shares of CVS Health from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Friday, February 9th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $86.27.
About CVS Health
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.